Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis.
Reumatismo
; 65(3): 134-7, 2013 Jul 24.
Article
en En
| MEDLINE
| ID: mdl-23884030
In axial spondyloarthritis (SpA), the efficacy of certolizumab pegol (CZP), a novel pegylated anti-tumor necrosis factor alpha drug has not been investigated. We report that CZP showed a rapid effectiveness, assessed clinically and by magnetic resonance imaging, in a patient with a non-radiographic axial SpA, classified according to Assessment in SpondyloArthritis International Society (ASAS) criteria. This case suggests that CZP could be considered an useful treatment in non-radiographic axial SpA, supporting that an earlier therapeutic approach could play a relevant role in the management of the disease.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Polietilenglicoles
/
Fragmentos Fab de Inmunoglobulinas
/
Espondiloartritis
/
Anticuerpos Monoclonales Humanizados
/
Inmunosupresores
Tipo de estudio:
Diagnostic_studies
Límite:
Adult
/
Female
/
Humans
Idioma:
En
Revista:
Reumatismo
Año:
2013
Tipo del documento:
Article
País de afiliación:
Italia
Pais de publicación:
Italia